| Name | TP53 |
|---|---|
| Synonyms | Antigen NY CO 13; Cellular tumor antigen p53; LFS 1; LFS1; P53; Phosphoprotein p53; TP53; TRP53… |
| Name | ACC |
|---|---|
| CAS | 1-aminocyclopropanecarboxylic acid |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 19679062 | de Lima Mde D, Marques YM, Alves Sde M Jr, Freitas VM, Soares FA, de Araujo VC, Pinto Ddos S Jr, Mantesso A: MDM2, P53, P21WAF1 and pAKT protein levels in genesis and behaviour of adenoid cystic carcinoma. Cancer Epidemiol. 2009 Aug;33(2):142-6. Epub 2009 Jun 6. |
4(0,0,0,4) | Details |
| 18762572 | Russell-Swetek A, West AN, Mintern JE, Jenkins J, Rodriguez-Galindo C, Ribeiro R, Zambetti GP: Identification of a novel TP53 germline mutation E285V in a rare case of paediatric adrenocortical carcinoma and choroid plexus carcinoma. J Med Genet. 2008 Sep;45(9):603-6. |
4(0,0,0,4) | Details |
| 18332873 | Bernheim A, Toujani S, Saulnier P, Robert T, Casiraghi O, Validire P, Temam S, Menard P, Dessen P, Fouret P: High-resolution array comparative genomic hybridization analysis of human bronchial and salivary adenoid cystic carcinoma. Lab Invest. 2008 May;88(5):464-73. Epub 2008 Mar 10. The minimal common regions of deletions contained the CDKN2A/CDKN2B, TP53, and LIMA1 tumor suppressor genes. |
2(0,0,0,2) | Details |
| 19217709 | Duarte ML, de Moraes E, Pontes E, Schluckebier L, de Moraes JL, Hainaut P, Ferreira CG: Role of p53 in the induction of cyclooxygenase-2 by cisplatin or paclitaxel in non-small cell lung cancer cell lines. Cancer Lett. 2009 Jun 28;279(1):57-64. Epub 2009 Feb 13. Therefore, TP53 status could change tumor sensitivity to chemotherapy through induction of the anti-apoptotic protein COX-2. |
2(0,0,0,2) | Details |
| 19500768 | Bertherat J, Bertagna X: Pathogenesis of adrenocortical cancer. . Best Pract Res Clin Endocrinol Metab. 2009 Apr;23(2):261-71. Somatic mutations of the tumour suppressor gene TP53 are observed in a third of ACCs. |
2(0,0,0,2) | Details |
| 19168381 | Chong LT, Pitera JW, Swope WC, Pande VS: Comparison of computational approaches for predicting the effects of missense mutations on p53 function. J Mol Graph Model. 2009 Jun-Jul;27(8):978-82. Epub 2008 Dec 27. Cheatham 3rd., Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models, Acc. Res. 33 (12) (2000) 889-897] to evaluate the effects of all possible missense mutations on dimerization of the oligomerization domain (residues 326-355) of tumor suppressor p53. |
1(0,0,0,1) | Details |
| 18366613 | Yang JY, Yang MQ, Luo Z, Ma Y, Li J, Deng Y, Huang X: A hybrid machine learning-based method for classifying the Cushing's Syndrome with comorbid adrenocortical lesions. BMC Genomics. 2008;9 Suppl 1:S23. We have also used immunohistochemistry techniques to measure the gene expression profiles from a number of antigens such as cyclin E, P27KIP1, FHIT, Ki-67, PCNA, Bax, Bcl-2, P53, Fas, FasL and hTERT in several particular types of neuroendocrine tumors such as pheochromocytomas, paragangliomas, and the adrenocortical carcinomas (ACC), adenomas (ACA), and hyperplasia (ACH) involved with Cushing's syndrome. |
1(0,0,0,1) | Details |